Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 64
13
Diseases
14
Unique genes
0.400
Avg. similarity score
Aphasia
Most-connected disease (7 links)
Disease
Searched: Spinal cord compression
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Spinal cord compression
Aphasia
Postictal aphasia
Commisural aphasia
Dejerine-lichtheim phenomenon
Cardiac tamponade
Dysphasia
Syntactic aphasia
Dermatitis herpetiformis
Refractory anemia
Pregnancy disorder
Extrinsic allergic alveolitis
cutis laxa, autosomal dominant 1
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Aphasia | 7 | 7 | 2 |
| Postictal aphasia | 7 | 7 | 2 |
| Spinal cord compression | 7 | 7 | 3 |
| Commisural aphasia | 6 | 6 | 2 |
| Dejerine-lichtheim phenomenon | 6 | 6 | 2 |
| Cardiac tamponade | 5 | 5 | 1 |
| Dysphasia | 5 | 5 | 4 |
| Syntactic aphasia | 5 | 5 | 2 |
| Dermatitis herpetiformis | 4 | 4 | 3 |
| Refractory anemia | 4 | 4 | 1 |
| Pregnancy disorder | 3 | 3 | 4 |
| Extrinsic allergic alveolitis | 2 | 2 | 4 |
| cutis laxa, autosomal dominant 1 | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| PLAT | 8 / 13 | Aphasia, Cardiac tamponade, Commisural aphasia, Dejerine-lichtheim phenomenon and 4 more |
| L1CAM | 6 / 13 | Aphasia, Commisural aphasia, Dejerine-lichtheim phenomenon, Dysphasia and 2 more |
| TNF | 5 / 13 | Dermatitis herpetiformis, Extrinsic allergic alveolitis, Pregnancy disorder, Refractory anemia and 1 more |
| ELN | 2 / 13 | cutis laxa, autosomal dominant 1, Dermatitis herpetiformis |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Herpes simplex virus 1 infection | KEGG | 4 / 182 | 18.9× | 4.54e-5 | 1.20e-3 ✓ sig. |
| IL-17 signaling pathway | KEGG | 3 / 94 | 27.4× | 1.59e-4 | 3.28e-3 ✓ sig. |
| Viral protein interaction with cytokine and cytokine receptor | KEGG | 3 / 100 | 25.7× | 1.91e-4 | 3.81e-3 ✓ sig. |
| TNF signaling pathway | KEGG | 3 / 119 | 21.6× | 3.19e-4 | 5.71e-3 ✓ sig. |
| Fluid shear stress and atherosclerosis | KEGG | 3 / 141 | 18.3× | 5.24e-4 | 8.44e-3 ✓ sig. |
| Type I diabetes mellitus | KEGG | 2 / 44 | 39.0× | 1.16e-3 | 1.56e-2 ✓ sig. |
| Interleukin-10 signaling | Reactome | 2 / 47 | 36.5× | 1.32e-3 | 1.72e-2 ✓ sig. |
| Malaria | KEGG | 2 / 50 | 34.3× | 1.50e-3 | 1.89e-2 ✓ sig. |
| Lipid and atherosclerosis | KEGG | 3 / 216 | 11.9× | 1.80e-3 | 2.16e-2 ✓ sig. |
| Human cytomegalovirus infection | KEGG | 3 / 226 | 11.4× | 2.05e-3 | 2.37e-2 ✓ sig. |
| TNFR2 non-canonical NF-kB pathway | Reactome | 2 / 69 | 24.9× | 2.83e-3 | 3.00e-2 ✓ sig. |
| Antigen processing and presentation | KEGG | 2 / 81 | 21.2× | 3.88e-3 | 3.74e-2 ✓ sig. |
| Cytokine-cytokine receptor interaction | KEGG | 3 / 298 | 8.6× | 4.49e-3 | 4.14e-2 ✓ sig. |
| L1CAM interactions | Reactome | 1 / 4 | 214× | 4.66e-3 | 4.24e-2 ✓ sig. |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | Reactome | 1 / 4 | 214× | 4.66e-3 | 4.24e-2 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| positive regulation of chronic inflammatory response to antigenic stimulus | GO:0002876 | 2 / 2 | 1,335× | 5.21e-7 | 4.89e-5 ✓ sig. |
| animal organ morphogenesis | GO:0009887 | 4 / 130 | 41.1× | 2.12e-6 | 1.54e-4 ✓ sig. |
| response to isolation stress | GO:0035900 | 2 / 4 | 667× | 3.12e-6 | 2.10e-4 ✓ sig. |
| positive regulation of humoral immune response mediated by circulating immunoglobulin | GO:0002925 | 2 / 5 | 534× | 5.21e-6 | 3.16e-4 ✓ sig. |
| response to hypoxia | GO:0001666 | 4 / 176 | 30.3× | 7.07e-6 | 4.05e-4 ✓ sig. |
| humoral immune response | GO:0006959 | 3 / 58 | 69.0× | 1.01e-5 | 5.33e-4 ✓ sig. |
| positive regulation of glial cell proliferation | GO:0060252 | 2 / 22 | 121× | 1.19e-4 | 3.52e-3 ✓ sig. |
| positive regulation of mitotic nuclear division | GO:0045840 | 2 / 29 | 92.1× | 2.09e-4 | 5.32e-3 ✓ sig. |
| response to lipopolysaccharide | GO:0032496 | 3 / 161 | 24.9× | 2.13e-4 | 5.38e-3 ✓ sig. |
| regulation of synaptic transmission, glutamatergic | GO:0051966 | 2 / 33 | 80.9× | 2.72e-4 | 6.37e-3 ✓ sig. |
| negative regulation of fibroblast proliferation | GO:0048147 | 2 / 35 | 76.3× | 3.06e-4 | 6.95e-3 ✓ sig. |
| positive regulation of extrinsic apoptotic signaling pathway | GO:2001238 | 2 / 38 | 70.3× | 3.61e-4 | 7.81e-3 ✓ sig. |
| blood circulation | GO:0008015 | 2 / 41 | 65.1× | 4.20e-4 | 8.69e-3 ✓ sig. |
| positive regulation of nitric oxide biosynthetic process | GO:0045429 | 2 / 42 | 63.6× | 4.41e-4 | 8.96e-3 ✓ sig. |
| vasodilation | GO:0042311 | 2 / 50 | 53.4× | 6.25e-4 | 1.14e-2 ✓ sig. |